DILLICO’S All-ScaleFlow™– BASED EQUIPMENT
combines game-changing innovations with robust and proven technologies.
All-ScaleFlow™ is the world’s first All-Scale-in-One mRNA manufacturing solution.
It offers an entirely new approach that enables the end-to-end production of mRNA-LNP, from In-Vitro Transcription to LNP encapsulation at any scale, using the same equipment and process design space.
Reshape the biopharmaceutical industry landscape
with on-demand production of next-generation therapeutics at local levels!
Dillico’s global team of innovators, scientists, and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology.
Our End-to-End Ready-to-Use solution enables the swift development, customization, and production of mRNA vaccines and therapies at any scale. This not only opens doors for new players to enter the mRNA market but also allows for regional production.
This means improved global healthcare access, especially for low- and medium-income countries combating regional diseases and emerging epidemics.
DILLICO’S All-ScaleFlow™– BASED EQUIPMENT
combines game-changing innovations with robust and proven technologies.
All-ScaleFlow™ is the world’s first All-Scale-in-One mRNA manufacturing solution.
It offers an entirely new approach that enables the end-to-end production of mRNA-LNP, from In-Vitro Transcription to LNP encapsulation at any scale, using the same equipment and process design space.
Reshape the biopharmaceutical industry landscape
with on-demand production of next-generation therapeutics at local levels!
Dillico’s global team of innovators, scientists, and industry experts believes that continuous manufacturing can unlock the full potential of mRNA technology.
Our End-to-End Ready-to-Use solution enables the swift development, customization, and production of mRNA vaccines and therapies at any scale. This not only opens doors for new players to enter the mRNA market but also allows for regional production.
This means improved global healthcare access, especially for low- and medium-income countries combating regional diseases and emerging epidemics.
FLEXIBILITY
Adapted production scale
Capacity
Micro factory
to large manufacturing
Product
Suited to all
types of mRNA-LNP
Localization
A 5 sq/m footprint
automated equipment
